A new vision for keratoconus: Epioxa redefines treatment after a decade-long wait
Epioxa by Glaukos Corp received US Food and Drug Administration (FDA) approval on 20 October as the first and only …
Post
-
-
How next-gen medical textiles combine comfort, safety, and sustainability
Every year, millions of disposable gowns end up in medical waste incinerators. But a new generation of sustainable textiles is …
-
Massive sales for weight loss drugs spur Eli Lilly’s Q3
As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of …
-
Debiopharm and NetTargets to identify synergistic drug combos for ADCs
Swiss-based Debiopharm has formed a research partnership with South Korea-based AI drug discovery company NetTargets for the identification and development …
-
Helex secures $3.5m to advance kidney disease therapies
Helex has raised $3.5m in an oversubscribed seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for …
-
Health Canada grants NOC for AstraZeneca’s breast cancer therapy
Health Canada has issued a notice of compliance (NOC) for AstraZeneca’shuman epidermal growth factor receptor 2 (HER2)-directed antibody drug conjugate …
-
FDA looks to simplify biosimilar development with new draft guidance
The US Food and Drug Administration (FDA) has debuted new draft guidance that aims to streamline and expedite the biosimilar …
-
Magazine: Cleanroom chronicles
With tighter regulations around biopharma manufacturing and the emergence of advanced therapies, cleanroom design is being fundamentally reshaped. This month's …
-
Novo Nordisk locks horns with Pfizer in late bid for Metsera
Pfizer’s agreed takeover Metsera could be in jeopardy, after Novo Nordisk submitted a rival bid to acquire the obesity biotech. Novo …
-
Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion
Eli Lilly will invest more than $1.2bn into its manufacturing site in Puerto Rico, as the drugmaker looks to assemble …
-
Dewpoint receives FDA orphan drug designation for DPTX3186
Dewpoint Therapeutics has received the US Food and Drug Administration’s (FDA) orphan drug designation (ODD) for DPTX3186, a small-molecule condensate …
-
From pilot to production: Scaling lyophilization with confidence
Lyophilization is a vital tool to maintain product quality, extend shelf life, and protect delicate compounds. Many parenteral formulations and …
-
Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing
Two of the world’s largest pharmaceutical companies, Pfizer (New York, US) and Roche (Basel, Switzerland), have unveiled more than $10bn …
-
Seres to obtain $3.6m from CARB-X for SER-155 development
Seres Therapeutics is to receive up to $3.6m in further non-dilutive funding from the international non-profit partnership, Combating Antibiotic-Resistant Bacteria …
-
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
Backed by $70m in Series A funding, Elevara Medicines has launched to advance its CDK4/6 inhibitor, which belongs to a …
